Global Respiratory Drugs Market 2018-2024
Respiratory disorders, which affect mechanisms of the respiratory system such as the lungs and airway, are a wide-ranging chronic disease with a diversity of underlying causes, ranging from inherited mutations to pathological inflammation. The respiratory disorders market is dominated by long-acting beta-agonist (LABA) and long-acting muscarinic antagonist (LAMA) therapies for chronic obstructive pulmonary disease (COPD) and asthma. These drugs stimulate muscles surrounding the bronchial tubes to suppress and open the airways.
Respiratory therapy area consists of signs that affect the lungs, bronchi, trachea, larynx, pharynx and nose in various ways, such as the scarring of lung tissue or the extreme production of mucus. Respiratory disease generally results in breathing difficulties, that can lead to troubles in sleep, wheezing, anxiety, and stress. During worse condition, shortness of breath (dyspnea) can limit physical activity, affecting both the quality of life and life expectancy of sufferers. The cause of respiratory disorders contrasts significantly across each indication and comprises factors such as environment, occupation, genetic predisposition, and aging.
Report Scope:
Report Category: Pharmacuticals / Healthcare
Therapy Type
Asthma
Chronic Obstructive Pulmonary Disease
Idiopathic Pulmonary Fibrosis
Cystic Fibrosis
End-user
Hospitals
Ambulatory Care
Others
Regions
North America
Europe
Asia Pacific
Rest of the World
Industry Outlook: Market Trends and Drivers, Restraints, and Opportunities
Respiratory therapy area consists of signs that affect the lungs, bronchi, trachea, larynx, pharynx and nose in various ways, such as the scarring of lung tissue or the extreme production of mucus. Respiratory disease generally results in breathing difficulties, that can lead to troubles in sleep, wheezing, anxiety, and stress. During worse condition, shortness of breath (dyspnea) can limit physical activity, affecting both the quality of life and life expectancy of sufferers. The cause of respiratory disorders contrasts significantly across each indication and comprises factors such as environment, occupation, genetic predisposition, and aging.
Report Scope:
Report Category: Pharmacuticals / Healthcare
Therapy Type
Asthma
Chronic Obstructive Pulmonary Disease
Idiopathic Pulmonary Fibrosis
Cystic Fibrosis
End-user
Hospitals
Ambulatory Care
Others
Regions
North America
Europe
Asia Pacific
Rest of the World
Industry Outlook: Market Trends and Drivers, Restraints, and Opportunities
1 INDUSTRY OUTLOOK
1.1 Industry Overview
1.2 Total Addressable Market
1.3 Industry Trends
2 REPORT OUTLINE
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions
3 MARKET SNAPSHOT
3.1 Market Definition – Infoholic Research
3.2 Segmented Addressable Market (SAM)
3.3 Importance of Respiratory Care
3.4 Trends of Respiratory Drugs Market
3.5 Related Markets
3.5.1 Oncology (Cancer) Drugs
3.5.2 Active pharmaceutical ingredients (APIs)
3.5.3 Over the counter drugs (OTC)
3.5.4 Diabetes Drugs
4 MARKET OUTLINE
4.1 Pipeline Products of Respiratory Drugs by Major Companies
4.2 Market Segmentation
4.3 Porter 5(Five) Forces
4.4 PEST Analysis
5 MARKET CHARACTERISTICS
5.1 Market Dynamics of Respiratory Drugs Market
5.1.1 Drivers
5.1.1.1 Increasing Aging Population
5.1.1.2 Rising prevalence of respiratory diseases
5.1.1.3 High prevalence of tobacco smoking
5.1.2 Opportunities
5.1.2.1 Supportive initiatives from government and other organizations
5.1.2.2 Huge pool of undiagnosed chronic obstructive pulmonary disease population
5.1.3 Restraints
5.1.3.1 Expiry of patents for blockbuster drugs
5.1.3.2 Complex drug development process
5.1.4 DRO – Impact Analysis
5.1.5 Key Stakeholders
6 APPLICATION: MARKET SIZE AND ANALYSIS
6.1 Overview
6.2 Asthma
6.3 Chronic Obstructive Pulmonary Disease (COPD)
6.4 Cystic Fibrosis
6.5 Allergic Rhinitis
6.6 Others
7 REGIONS: MARKET SIZE AND ANALYSIS
7.1 Overview
7.2 North America
7.2.1 Overview
7.2.2 United States
7.2.3 Canada
7.3 Europe
7.3.1 Overview
7.3.2 United Kingdom
7.3.3 Germany
7.3.4 France
7.4 APAC
7.4.1 Overview
7.4.2 India
7.4.3 China
7.4.4 Japan
7.5 Rest of the World
7.5.1 Overview
7.5.2 Middle East
7.5.3 Brazil
7.5.4 Mexico
8 COMPETITIVE LANDSCAPE
9 VENDOR PROFILES
9.1 Novartis AG
9.1.1 Overview
9.1.2 Business Unit
9.1.3 Geographic Presence
9.1.4 Business Focus
9.1.5 SWOT Analysis
9.1.6 Business Strategy
9.2 GlaxoSmithKline plc
9.2.1 Overview
9.2.2 Geographic Presence
9.2.3 Business Focus
9.2.4 SWOT Analysis
9.2.5 Business Strategy
9.3 Astra Zenca PLC
9.3.1 Overview
9.3.2 Geographic Presence
9.3.3 Business Focus
9.3.4 SWOT Analysis
9.3.5 Business Strategy
9.4 F.Hoffmann-La Roche Ltd.
9.4.1 Overview
9.4.2 Business Unit
9.4.3 Geographic Presence
9.4.4 Business Focus
9.4.5 SWOT Analysis
9.4.6 Business Strategy
9.5 Vertex Pharmaceuticals Inc.
9.5.1 Overview
9.5.2 Geographic Presence
9.5.3 Business Focus
9.5.4 SWOT Analysis
9.5.5 Business Strategy
10 COMPANIES TO WATCH FOR
10.1 Boehringer Ingelheim GmbH
10.1.1 Overview
10.1.2 Highlights
10.2 Teva Pharmaceutical Industries Ltd.
10.2.1 Overview
10.2.2 Highlights:
10.3 Gilead Sciences Inc.
10.3.1 Overview
10.3.2 Highlights:
10.4 Bayer AG
10.4.1 Overview
10.5 Pfizer Inc.
10.5.1 Overview
10.5.2 Highlights
10.6 Bristol-Myers Squibb Co.
10.6.1 Overview
10.7 Merck & Co.
10.7.1 Overview
10.7.2 Highlights:
10.8 Sanofi
10.8.1 Overview
10.9 Mallinckrodt plc
10.9.1 Overview
Annexure
Abbreviations
?
Tables
Table 1 RESPIRATORY DRUGS: PIPELINE PRODUCTS
Table 2 PATENT EXPIRATION OF RESPIRATORY DRUGS
Table 3 RESPIRATORY DRUGS MARKET REVENUE BY APPLICATION, 2017–2024 ($MILLION)
Table 4 RESPIRATORY DRUGS MARKET REVENUE BY REGIONS, 2017–2024 ($MILLION)
Table 5 MAJOR RESPIRATORY DRUGS MARKET ($MILLION)
Table 6 NOVARTIS AG: OFFERINGS
Table 7 NOVARTIS AG: RECENT DEVELOPMENTS
Table 8 NOVARTIS AG RESPIRATORY DRUGS PIPELINE MOLECULES
Table 9 GLAXOSMITHKLINE PLC: OFFERINGS
Table 10 GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS
Table 11 ASTRA ZENCA PLC: OFFERINGS
Table 12 ASTRA ZENCA PLC: RECENT DEVELOPMENTS
Table 13 F. HOFFMANN-LA ROCHE LTD.: OFFERINGS
Table 14 F. HOFFMANN-LA ROCHE LTD.: RECENT DEVELOPMENTS
Table 15 ROCHE: PIPELINE MOLECULES IN RESPIRATORY DRUGS SEGMENT
Table 16 VERTEX PHARMACEUTICALS INC.: OFFERINGS
Table 17 VERTEX PHARMACEUTICALS INC.: RECENT DEVELOPMENTS
Table 18 VERTEX PHARMACEUTICALS: PIPELINE MOLECULES IN RESPIRATORY DRUGS SEGMENT
Table 19 BOEHRINGER INGELHEIM GMBH: OVERVIEW
Table 20 TEVA PHARMACEUTICAL INDUSTRIES LTD.: OVERVIEW
Table 21 GILEAD SCIENCES INC.: OVERVIEW
Table 22 BAYER AG: OVERVIEW
Table 23 BAYER AG: RECENT DEVELOPMENTS
Table 24 PFIZER INC. OVERVIEW
Table 25 PFIZER INC.: RECENT DEVELOPMENTS
Table 26 BRISTOL-MYERS SQUIBB CO.: OVERVIEW
Table 27 BRISTOL-MYERS SQUIBB CO.: KEY DEVELOPMENTS
Table 28 MERCK & CO.: OVERVIEW
Table 29 MERCK & CO.: RECENT DEVELOPMENTS
Table 30 SANOFI: OVERVIEW
Table 31 SANOFI: RECENT DEVELOPMENTS
Table 32 MALLINCKRODT PLC: OVERVIEW
Charts
Chart 1 RESEARCH METHODOLOGY OF GLOBAL RESPIRATORY DRUGS MARKET
Chart 2 GLOBAL RESPIRATORY DRUGS MARKET REVENUE, 2017-2024 ($MILLION)
Chart 3 SEGMENTATION OF GLOBAL REPIRATORY DRUGS MARKET
Chart 4 PORTER 5 FORCES OF RESPIRATORY DRUGS MARKET
Chart 5 PEST ANALYSIS OF REPIRATORY DRUGS MARKET
Chart 6 MARKET DYNAMICS – DRO ANALYSIS
Chart 7 WORLD POPULATION AGED 65 YEARS AND ABOVE, 1960-2060 (%)
Chart 8 DRO – IMPACT ANALYSIS OF GLOBAL RESPIRATORY DRUGS MARKET
Chart 9 KEY STAKEHOLDERS
Chart 10 RESPIRATORY DRUGS MARKET BY APPLICATION SEGMENTATION, 2017 VS 2024 (%)
Chart 11 RESPIRATORY DRUGS MARKET REVENUE IN ASTHMA APPLICATION, 2017-2024 ($MILLION)
Chart 12 RESPIRATORY DRUGS MARKET REVENUE IN COPD APPLICATION, 2017-2024 ($MILLION)
Chart 13 RESPIRATORY DRUGS MARKET REVENUE IN CYSTIC FIBROSIS APPLICATION, 2017-2024 ($MILLION)
Chart 14 RESPIRATORY DRUGS MARKET REVENUE IN ALLERGIC RHINITIS APPLICATION, 2017-2024 ($MILLION)
Chart 15 RESPIRATORY DRUGS MARKET REVENUE IN OTHERS APPLICATION, 2017-2024 ($MILLION)
Chart 16 RESPIRATORY DRUGS MARKET BY REGIONAL SEGMENTATION, 2017 VS 2024 (%)
Chart 17 RESPIRATORY DRUGS MARKET REVENUE IN NORTH AMERICA, 2017-2024 ($MILLION)
Chart 18 RESPIRATORY DRUG MARKET REVENUE IN THE EUROPE REGION, 2017–2023 ($MILLION)
Chart 19 RESPIRATORY DRUGS MARKET REVENUE IN THE APAC REGION, 2017-2024 ($MILLION)
Chart 20 RESPIRATORY DRUGS MARKET REVENUE IN REST OF THE WORLD, 2017–2024 ($MILLION)
Chart 21 RESPIRATORY PIPELINE DRUGS IN THE MARKET
Chart 22 MARKET SHARE OF MAJOR PLAYERS-2017 (%)
Chart 23 NOVARTIS AG: OVERVIEW SNAPSHOT
Chart 24 NOVARTIS AG: BUSINESS UNITS
Chart 25 NOVARTIS AG: GEOGRAPHICAL PRESENCE
Chart 26 NOVARTIS AG: SWOT ANALYSIS
Chart 27 GLAXOSMITHKLINE PLC: OVERVIEW SNAPSHOT
Chart 28 GLAXOSMITHKLINE PLC: BUSINESS UNITS
Chart 29 GLAXOSMITHKLINE PLC: GEOGRAPHIC PRESENCE
Chart 30 GSK: REVENUE OF RESPIRATORY PORTFOLIO
Chart 31 GLAXOSMITHKLINE PLC: SWOT ANALYSIS
Chart 32 ASTRA ZENCA PLC: OVERVIEW SNAPSHOT
Chart 33 ASTRA ZENCA PLC: BUSINESS UNITS
Chart 34 ASTRA ZENCA PLC: GEOGRAPHIC PRESENCE
Chart 35 ASTRA ZENCA PLC: SWOT ANALYSIS
Chart 36 F. HOFFMANN-LA ROCHE LTD.: OVERVIEW SNAPSHOT
Chart 37 F. HOFFMANN.LA ROCHE LTD.: BUSINESS UNITS
Chart 38 F. HOFFMANN-LA ROCHE: GEOGRAPHICAL PRESENCE
Chart 39 F. HOFFMANN-LA ROCHE LTD.: SWOT ANALYSIS
Chart 40 VERTEX PHARMACEUTICALS INC.: OVERVIEW SNAPSHOT
Chart 41 VERTEX PHARMACEUTICALS INC.: GEOGRAPHICAL PRESENCE
Chart 42 VERTEX PHARMACEUTICALS INC.: SWOT ANALYSIS
1.1 Industry Overview
1.2 Total Addressable Market
1.3 Industry Trends
2 REPORT OUTLINE
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions
3 MARKET SNAPSHOT
3.1 Market Definition – Infoholic Research
3.2 Segmented Addressable Market (SAM)
3.3 Importance of Respiratory Care
3.4 Trends of Respiratory Drugs Market
3.5 Related Markets
3.5.1 Oncology (Cancer) Drugs
3.5.2 Active pharmaceutical ingredients (APIs)
3.5.3 Over the counter drugs (OTC)
3.5.4 Diabetes Drugs
4 MARKET OUTLINE
4.1 Pipeline Products of Respiratory Drugs by Major Companies
4.2 Market Segmentation
4.3 Porter 5(Five) Forces
4.4 PEST Analysis
5 MARKET CHARACTERISTICS
5.1 Market Dynamics of Respiratory Drugs Market
5.1.1 Drivers
5.1.1.1 Increasing Aging Population
5.1.1.2 Rising prevalence of respiratory diseases
5.1.1.3 High prevalence of tobacco smoking
5.1.2 Opportunities
5.1.2.1 Supportive initiatives from government and other organizations
5.1.2.2 Huge pool of undiagnosed chronic obstructive pulmonary disease population
5.1.3 Restraints
5.1.3.1 Expiry of patents for blockbuster drugs
5.1.3.2 Complex drug development process
5.1.4 DRO – Impact Analysis
5.1.5 Key Stakeholders
6 APPLICATION: MARKET SIZE AND ANALYSIS
6.1 Overview
6.2 Asthma
6.3 Chronic Obstructive Pulmonary Disease (COPD)
6.4 Cystic Fibrosis
6.5 Allergic Rhinitis
6.6 Others
7 REGIONS: MARKET SIZE AND ANALYSIS
7.1 Overview
7.2 North America
7.2.1 Overview
7.2.2 United States
7.2.3 Canada
7.3 Europe
7.3.1 Overview
7.3.2 United Kingdom
7.3.3 Germany
7.3.4 France
7.4 APAC
7.4.1 Overview
7.4.2 India
7.4.3 China
7.4.4 Japan
7.5 Rest of the World
7.5.1 Overview
7.5.2 Middle East
7.5.3 Brazil
7.5.4 Mexico
8 COMPETITIVE LANDSCAPE
9 VENDOR PROFILES
9.1 Novartis AG
9.1.1 Overview
9.1.2 Business Unit
9.1.3 Geographic Presence
9.1.4 Business Focus
9.1.5 SWOT Analysis
9.1.6 Business Strategy
9.2 GlaxoSmithKline plc
9.2.1 Overview
9.2.2 Geographic Presence
9.2.3 Business Focus
9.2.4 SWOT Analysis
9.2.5 Business Strategy
9.3 Astra Zenca PLC
9.3.1 Overview
9.3.2 Geographic Presence
9.3.3 Business Focus
9.3.4 SWOT Analysis
9.3.5 Business Strategy
9.4 F.Hoffmann-La Roche Ltd.
9.4.1 Overview
9.4.2 Business Unit
9.4.3 Geographic Presence
9.4.4 Business Focus
9.4.5 SWOT Analysis
9.4.6 Business Strategy
9.5 Vertex Pharmaceuticals Inc.
9.5.1 Overview
9.5.2 Geographic Presence
9.5.3 Business Focus
9.5.4 SWOT Analysis
9.5.5 Business Strategy
10 COMPANIES TO WATCH FOR
10.1 Boehringer Ingelheim GmbH
10.1.1 Overview
10.1.2 Highlights
10.2 Teva Pharmaceutical Industries Ltd.
10.2.1 Overview
10.2.2 Highlights:
10.3 Gilead Sciences Inc.
10.3.1 Overview
10.3.2 Highlights:
10.4 Bayer AG
10.4.1 Overview
10.5 Pfizer Inc.
10.5.1 Overview
10.5.2 Highlights
10.6 Bristol-Myers Squibb Co.
10.6.1 Overview
10.7 Merck & Co.
10.7.1 Overview
10.7.2 Highlights:
10.8 Sanofi
10.8.1 Overview
10.9 Mallinckrodt plc
10.9.1 Overview
Annexure
Abbreviations
?
Tables
Table 1 RESPIRATORY DRUGS: PIPELINE PRODUCTS
Table 2 PATENT EXPIRATION OF RESPIRATORY DRUGS
Table 3 RESPIRATORY DRUGS MARKET REVENUE BY APPLICATION, 2017–2024 ($MILLION)
Table 4 RESPIRATORY DRUGS MARKET REVENUE BY REGIONS, 2017–2024 ($MILLION)
Table 5 MAJOR RESPIRATORY DRUGS MARKET ($MILLION)
Table 6 NOVARTIS AG: OFFERINGS
Table 7 NOVARTIS AG: RECENT DEVELOPMENTS
Table 8 NOVARTIS AG RESPIRATORY DRUGS PIPELINE MOLECULES
Table 9 GLAXOSMITHKLINE PLC: OFFERINGS
Table 10 GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS
Table 11 ASTRA ZENCA PLC: OFFERINGS
Table 12 ASTRA ZENCA PLC: RECENT DEVELOPMENTS
Table 13 F. HOFFMANN-LA ROCHE LTD.: OFFERINGS
Table 14 F. HOFFMANN-LA ROCHE LTD.: RECENT DEVELOPMENTS
Table 15 ROCHE: PIPELINE MOLECULES IN RESPIRATORY DRUGS SEGMENT
Table 16 VERTEX PHARMACEUTICALS INC.: OFFERINGS
Table 17 VERTEX PHARMACEUTICALS INC.: RECENT DEVELOPMENTS
Table 18 VERTEX PHARMACEUTICALS: PIPELINE MOLECULES IN RESPIRATORY DRUGS SEGMENT
Table 19 BOEHRINGER INGELHEIM GMBH: OVERVIEW
Table 20 TEVA PHARMACEUTICAL INDUSTRIES LTD.: OVERVIEW
Table 21 GILEAD SCIENCES INC.: OVERVIEW
Table 22 BAYER AG: OVERVIEW
Table 23 BAYER AG: RECENT DEVELOPMENTS
Table 24 PFIZER INC. OVERVIEW
Table 25 PFIZER INC.: RECENT DEVELOPMENTS
Table 26 BRISTOL-MYERS SQUIBB CO.: OVERVIEW
Table 27 BRISTOL-MYERS SQUIBB CO.: KEY DEVELOPMENTS
Table 28 MERCK & CO.: OVERVIEW
Table 29 MERCK & CO.: RECENT DEVELOPMENTS
Table 30 SANOFI: OVERVIEW
Table 31 SANOFI: RECENT DEVELOPMENTS
Table 32 MALLINCKRODT PLC: OVERVIEW
Charts
Chart 1 RESEARCH METHODOLOGY OF GLOBAL RESPIRATORY DRUGS MARKET
Chart 2 GLOBAL RESPIRATORY DRUGS MARKET REVENUE, 2017-2024 ($MILLION)
Chart 3 SEGMENTATION OF GLOBAL REPIRATORY DRUGS MARKET
Chart 4 PORTER 5 FORCES OF RESPIRATORY DRUGS MARKET
Chart 5 PEST ANALYSIS OF REPIRATORY DRUGS MARKET
Chart 6 MARKET DYNAMICS – DRO ANALYSIS
Chart 7 WORLD POPULATION AGED 65 YEARS AND ABOVE, 1960-2060 (%)
Chart 8 DRO – IMPACT ANALYSIS OF GLOBAL RESPIRATORY DRUGS MARKET
Chart 9 KEY STAKEHOLDERS
Chart 10 RESPIRATORY DRUGS MARKET BY APPLICATION SEGMENTATION, 2017 VS 2024 (%)
Chart 11 RESPIRATORY DRUGS MARKET REVENUE IN ASTHMA APPLICATION, 2017-2024 ($MILLION)
Chart 12 RESPIRATORY DRUGS MARKET REVENUE IN COPD APPLICATION, 2017-2024 ($MILLION)
Chart 13 RESPIRATORY DRUGS MARKET REVENUE IN CYSTIC FIBROSIS APPLICATION, 2017-2024 ($MILLION)
Chart 14 RESPIRATORY DRUGS MARKET REVENUE IN ALLERGIC RHINITIS APPLICATION, 2017-2024 ($MILLION)
Chart 15 RESPIRATORY DRUGS MARKET REVENUE IN OTHERS APPLICATION, 2017-2024 ($MILLION)
Chart 16 RESPIRATORY DRUGS MARKET BY REGIONAL SEGMENTATION, 2017 VS 2024 (%)
Chart 17 RESPIRATORY DRUGS MARKET REVENUE IN NORTH AMERICA, 2017-2024 ($MILLION)
Chart 18 RESPIRATORY DRUG MARKET REVENUE IN THE EUROPE REGION, 2017–2023 ($MILLION)
Chart 19 RESPIRATORY DRUGS MARKET REVENUE IN THE APAC REGION, 2017-2024 ($MILLION)
Chart 20 RESPIRATORY DRUGS MARKET REVENUE IN REST OF THE WORLD, 2017–2024 ($MILLION)
Chart 21 RESPIRATORY PIPELINE DRUGS IN THE MARKET
Chart 22 MARKET SHARE OF MAJOR PLAYERS-2017 (%)
Chart 23 NOVARTIS AG: OVERVIEW SNAPSHOT
Chart 24 NOVARTIS AG: BUSINESS UNITS
Chart 25 NOVARTIS AG: GEOGRAPHICAL PRESENCE
Chart 26 NOVARTIS AG: SWOT ANALYSIS
Chart 27 GLAXOSMITHKLINE PLC: OVERVIEW SNAPSHOT
Chart 28 GLAXOSMITHKLINE PLC: BUSINESS UNITS
Chart 29 GLAXOSMITHKLINE PLC: GEOGRAPHIC PRESENCE
Chart 30 GSK: REVENUE OF RESPIRATORY PORTFOLIO
Chart 31 GLAXOSMITHKLINE PLC: SWOT ANALYSIS
Chart 32 ASTRA ZENCA PLC: OVERVIEW SNAPSHOT
Chart 33 ASTRA ZENCA PLC: BUSINESS UNITS
Chart 34 ASTRA ZENCA PLC: GEOGRAPHIC PRESENCE
Chart 35 ASTRA ZENCA PLC: SWOT ANALYSIS
Chart 36 F. HOFFMANN-LA ROCHE LTD.: OVERVIEW SNAPSHOT
Chart 37 F. HOFFMANN.LA ROCHE LTD.: BUSINESS UNITS
Chart 38 F. HOFFMANN-LA ROCHE: GEOGRAPHICAL PRESENCE
Chart 39 F. HOFFMANN-LA ROCHE LTD.: SWOT ANALYSIS
Chart 40 VERTEX PHARMACEUTICALS INC.: OVERVIEW SNAPSHOT
Chart 41 VERTEX PHARMACEUTICALS INC.: GEOGRAPHICAL PRESENCE
Chart 42 VERTEX PHARMACEUTICALS INC.: SWOT ANALYSIS
